INDENTUREAntigenics Inc /De/ • November 27th, 2001 • Biological products, (no disgnostic substances) • Massachusetts
AMONGAgreement and Plan of Merger • April 24th, 2001 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
Exhibit 2.2 FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT This FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (this "Amendment") is dated as of March 17, 2004 (the "Effective Date"), by and between ANTIGENICS INC., a Massachusetts corporation and a...Asset Purchase Agreement • April 1st, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
WITNESSETHLicense Agreement • February 3rd, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Florida
1 EXHIBIT 10.4 ANTIGENICS INC. INDEMNIFICATION AGREEMENT ------------------------- This Agreement dated ______________________ is between Antigenics Inc. (the "Company"), a Delaware corporation, and ______________________ (the "Indemnitee"), who is...Indemnification Agreement • November 30th, 1999 • Antigenics Inc /De/ • Delaware
EXHIBIT 4.2 ANTIGENICS INC. REGISTRATION RIGHTS AGREEMENT January 25, 2005 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made and entered into as of January 25, 2005, by and among Antigenics Inc., a Delaware...Registration Rights Agreement • January 25th, 2005 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
MiNK Therapeutics, Inc. (a Delaware corporation) 3,333,334 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 28th, 2021 • Agenus Inc • Biological products, (no disgnostic substances) • New York
2 3 filing pursuant to such Rule 424(b) (and Rule 434, if applicable) or from and after the time it is first provided to the Underwriters by the Company for such use. The term "Preliminary Prospectus" as used herein means the preliminary prospectus...Antigenics Inc /De/ • January 10th, 2000 • Biological products, (no disgnostic substances) • New York
Common Stock ($0.01 Par Value)Underwriting Agreement • January 27th, 2003 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
RecitalsLease • May 7th, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
FLEXIBLE STANDARDIZED 401(k) PROFIT SHARING PLAN ADOPTION AGREEMENT =========== ===================================================================== --------- ----------------------------------------------------------------------- SECTION 1. EMPLOYER...Antigenics Inc /De/ • January 10th, 2000 • Biological products, (no disgnostic substances)
RECITALSSublease Agreement • August 13th, 2002 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
LICENSE AGREEMENT -----------------License Agreement • November 30th, 1999 • Antigenics Inc /De/ • New York
Exhibit 10.1 This Agreement is dated June 21, 2004 and is made between Antigenics Therapeutics Limited having its registered offices at 25/28 North Wall Quay, Dublin 1 Registered No. 381308 ("The Company") and Peter Thornton of Dublin, Ireland ("Chief...Agreement • August 9th, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
AMENDMENT AGREEMENT The Letter Agreement of June 3, 1998 between Antigenics L.L.C. and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. is hereby amended as follows: -ON PAGE 1, THE INITIAL SIX LINES: "Gentlemen: We refer to our recent discussions...Amendment Agreement • January 10th, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
SECURITIES PURCHASE AGREEMENT (as amended to date)Securities Purchase Agreement • September 19th, 2013 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 18, 2013, between Agenus Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 99.1 AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • August 24th, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
RECITALSLicense Agreement • August 27th, 2003 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Connecticut
AGENUS INC. Common Stock (par value $0.01 per share) At Market Issuance Sales AgreementAgenus Inc • July 22nd, 2020 • Biological products, (no disgnostic substances) • New York
AGENUS INC. Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • October 18th, 2017 • Agenus Inc • Biological products, (no disgnostic substances) • New York
Agenus Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Exhibit 4.3 [Face of Security] ANTIGENICS INC. Certificate No. _______ [INSERT PRIVATE PLACEMENT LEGEND AND GLOBAL SECURITY LEGEND] 5.25% Convertible Senior Note due 2025 CUSIP No. ____________ Antigenics Inc., a Delaware corporation (the "COMPANY"),...Antigenics Inc /De/ • May 24th, 2005 • Biological products, (no disgnostic substances)
Common Stock ($0.01 Par Value)Underwriting Agreement • January 11th, 2002 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
RECITALS:Patent License Agreement • February 3rd, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
IT IS AGREED:Research Agreement • March 31st, 2005 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Connecticut
RECITALSStockholder Voting Agreement • April 24th, 2001 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
ANDAsset Purchase Agreement • April 1st, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 10.7 MASTER LOAN AND SECURITY AGREEMENT Master Loan and Security Agreement No. S7020, dated November 19, 1998 FINOVA TECHNOLOGY FINANCE, INC. ("we," "us" or "FINOVA") is willing to make a loan (the "Loan") to ANTIGENICS, LLC ("you" or...Master Loan and Security Agreement • November 30th, 1999 • Antigenics Inc /De/ • Arizona
RECITALSLicense Agreement • May 15th, 2003 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Connecticut
EXHIBIT 10.5 CUMMINGS PROPERTIES MANAGEMENT, INC. STANDARD FORM COMMERCIAL LEASE In consideration of the covenants herein contained, Cummings Properties Management, Inc., hereinafter called LESSOR, does hereby lease to ANTIGENICS, L.L.C. (A DE...1 • November 30th, 1999 • Antigenics Inc /De/ • New York
EXHIBIT 4.3 ANTIGENICS L.L.C. SUBSCRIPTION AGREEMENT Antigenics L.L.C. 630 Fifth Avenue Suite 2170 New York, New York 10111 Ladies and Gentlemen: 1. SUBSCRIPTION FOR UNITS. The undersigned, intending to be legally bound, hereby irrevocably applies to...Subscription Agreement • January 24th, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • New York
WITNESSETH:Employment Agreement • November 30th, 1999 • Antigenics Inc /De/ • New York
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 10th, 2013 • Agenus Inc • Biological products, (no disgnostic substances) • New York
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 15, 2013 (the “Effective Date”) among (a) SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”), and (b) AGENUS INC., a Delaware corporation (“Agenus”) and ANTIGENICS INC., a Massachusetts corporation (“Antigenics”) (Agenus and Antigenics are individually and collectively, jointly and severally, “Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
RECITALSRight of First Refusal Agreement • May 27th, 2004 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
AGENUS INC. 19,335,653 Shares of Common Stock1 UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2014 • Agenus Inc • Biological products, (no disgnostic substances) • Illinois
SUBSCRIPTION AGREEMENT FOR LIMITED PARTNERSHIP INTEREST IN APPLIED GENOMIC TECHNOLOGY CAPITAL FUND, L.P.Subscription Agreement • August 14th, 2000 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
